Dimethyl Itaconate Inhibits Melanogenesis in B16F10 Cells

Area of Science:

• Biochemistry
• Cell Biology
• Dermatology

Background:

• Itaconate is an endogenous metabolite involved in resolving inflammation.
• Melanogenesis, the process of melanin production, is crucial for skin pigmentation and UV protection.
• Dysregulation of melanogenesis can lead to hyperpigmentation disorders.

Purpose of the Study:

• To investigate the effect of dimethyl itaconate (DMI) on melanogenesis in B16F10 melanoma cells.
• To elucidate the molecular mechanisms underlying DMI's inhibitory effects on melanin production.
• To identify the key signaling pathways and molecular targets involved.

Main Methods:

• Cell culture of B16F10 melanoma cells.
• Assessment of melanin content and expression of melanogenesis-related genes (MITF, TYR, TRP-1, TRP-2).
• Analysis of signaling pathway components (MC1R, α-MSH, ERK1/2, KEAP1, NRF2) using molecular biology techniques.
• Structure-activity relationship (SAR) study of DMI.

Main Results:

• Dimethyl itaconate (DMI) significantly inhibited melanogenesis in B16F10 cells.
• DMI downregulated the expression of microphthalmia-associated transcription factor (MITF) and its target genes (TYR, TRP-1, TRP-2).
• DMI reduced melanocortin 1 receptor (MC1R) levels and α-melanocyte stimulating hormone (α-MSH) production, inhibiting ERK1/2 and MITF activities.
• The α,β-unsaturated carbonyl moiety of DMI was essential for inhibiting melanogenesis via the KEAP1-NRF2 pathway.
• Knockdown of NRF2 attenuated the inhibitory effect of DMI on melanogenesis.

Conclusions:

• DMI effectively inhibits melanogenesis through the regulation of the MC1R-ERK1/2-MITF axis.
• The KEAP1-NRF2 pathway plays a critical role in mediating DMI's anti-melanogenic effects.
• DMI represents a potential therapeutic agent for conditions associated with aberrant melanin production.